Javier Alonso-Llamazares
Overview
Explore the profile of Javier Alonso-Llamazares including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
86
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Simpson E, Eichenfield L, Alonso-Llamazares J, Draelos Z, Ferris L, Forman S, et al.
JAMA Dermatol
. 2024 Sep;
160(11):1161-1170.
PMID: 39292443
Importance: Safe, effective, and well-tolerated topical treatment options available for long-term use in patients with atopic dermatitis (AD) are limited and associated with low adherence rates. Objective: To evaluate efficacy...
2.
Gold L, Adam D, Albrecht L, Alonso-Llamazares J, Ferris L, Gooderham M, et al.
J Am Acad Dermatol
. 2024 Mar;
91(2):273-280.
PMID: 38556093
Background: Efficacy and/or safety profiles limit topical psoriasis treatments. Objective: Evaluate long-term effects of once-daily roflumilast cream 0.3% in patients with psoriasis. Methods: In this open-label phase 2 trial, adult...
3.
Blauvelt A, Draelos Z, Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, et al.
J Am Acad Dermatol
. 2024 Jan;
90(5):986-993.
PMID: 38253129
Background: The topical phosphodiesterase 4 inhibitor roflumilast has been studied in several dermatologic conditions. Objective: Roflumilast foam 0.3% is being investigated as a topical treatment for seborrheic dermatitis (SD). Methods:...
4.
Kircik L, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani A, Draelos Z, et al.
Br J Dermatol
. 2023 Jun;
189(4):392-399.
PMID: 37279795
Background: Scalp psoriasis affects most patients with psoriasis, but it can be difficult to treat. Objectives: To evaluate the efficacy and safety of once-daily roflumilast foam 0.3% on scalp and...
5.
Zirwas M, Draelos Z, DuBois J, Kircik L, Moore A, Gold L, et al.
JAMA Dermatol
. 2023 May;
159(6):613-620.
PMID: 37133856
Importance: Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. Objective: To assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis...
6.
Gold L, Alonso-Llamazares J, Draelos Z, Gooderham M, Kempers S, Kircik L, et al.
Am J Clin Dermatol
. 2022 Nov;
24(2):305-313.
PMID: 36370336
Background: Itch is the most bothersome symptom reported by patients with psoriasis. Safe and effective treatments for psoriasis that also address itch are needed. Objectives: To report effects of roflumilast...
7.
Aickara D, Patel S, Rosen J, Alonso-Llamazares J
Int J Dermatol
. 2022 Jul;
62(6):e358-e360.
PMID: 35816261
No abstract available.
8.
Adelglass J, Alonso-Llamazares J, Fenton J, Gold M, Schlessinger J, Smith S
J Drugs Dermatol
. 2022 Jan;
21(1):13-20.
PMID: 35005871
Objective: To compare the safety and efficacy of a novel hyaluronic acid injectable gel with 0.3% lidocaine (test device) with that of a commercially available injectable hyaluronic acid gel with...
9.
Gold L, Alonso-Llamazares J, Lacour J, Warren R, Tyring S, Kircik L, et al.
Adv Ther
. 2020 Sep;
37(11):4730-4753.
PMID: 32965655
Background: Psoriasis vulgaris is commonly treated with topical corticosteroids and vitamin D analogues. Although potent and super-potent topical corticosteroids are very effective at clearing psoriasis, with short-term reactive treatment durations,...
10.
Kircik L, Gold L, Teng J, Moore A, Cantrell W, Alonso-Llamazares J, et al.
J Drugs Dermatol
. 2020 Aug;
19(8):723-732.
PMID: 32845591
Calcipotriene 0.005% plus betamethasone dipropionate 0.064% (Cal/BD) aerosol foam is a topical agent indicated for the treatment of plaque psoriasis. While topical treatments are typically reserved for milder disease, in...